会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 34. 发明授权
    • Contact member and connector
    • 接触件和接头
    • US07811094B2
    • 2010-10-12
    • US12256625
    • 2008-10-23
    • Takashi KuwaharaSeiya TakahashiHiroshi Akimoto
    • Takashi KuwaharaSeiya TakahashiHiroshi Akimoto
    • H01R12/00
    • H01R13/2407H01R12/592
    • A contact member which is resistant to contact failure even if the environment of use is bad. A film is affixed to the surface of a long plate-shaped elastic body which is disposed between two to-be-connected objects. A electrically-conducting path which electrically connects between terminal portions of two to-be-connected objects is provided on the surface of the film. A first conductor contact portion which is capable of being brought into contact with the terminal portion of one of two to-be-connected objects is disposed at one end of the electrically-conducting path, and a second conductor contact portion which is capable of being brought into contact with the terminal portion of the other of two to-be-connected objects is disposed at the other end of the electrically-conducting path. A plurality of holes are formed in the first and second conductor contact portions.
    • 即使使用环境不良,也能够抵抗接触不良的接触部件。 薄膜固定在长板状弹性体的表面上,该长板状弹性体设置在两个被连接物体之间。 在膜的表面上设置导电路径,其电连接两个被连接物体的端子部分。 能够与两个待连接物体之一的端子部分接触的第一导体接触部分设置在导电路径的一端,以及第二导体接触部分,其能够被 与两个被连接物体中的另一个的端子部分接触设置在导电路径的另一端。 多个孔形成在第一和第二导体接触部分中。
    • 36. 发明授权
    • Method for diagnosing malignancy diseases
    • 诊断恶性肿瘤的方法
    • US5817025A
    • 1998-10-06
    • US864239
    • 1997-05-28
    • Sergei Grigorevich AlekseevNikolai Borisovich BrandtGalina Aleksandrovna MironovaHiroshi AkimotoKeiko Akimoto
    • Sergei Grigorevich AlekseevNikolai Borisovich BrandtGalina Aleksandrovna MironovaHiroshi AkimotoKeiko Akimoto
    • G01N33/49A61B10/00G01J3/44G01N15/00G01N21/49G01N21/85G01N33/52A61B6/00
    • G01J3/4412
    • The method for diagnosing malignancy diseases involving analysis of blood plasma by laser correlational spectroscopy (LSC) techniques includes the steps of: preparing a weak diluted solution of native blood plasma, determining a spectral density of light scattering intensity fluctuations within the frequency range between 1 and 1000 Hz, distinguishing a spectrum core and making a diagnosis from a frequency of a maximum and an intensity-to-half-width ratio of a spectrum core envelope, a malignancy disease being detected when the diagnostic parameters are less than the appropriate rates. The apparatus for diagnosing malignancy diseases includes a nephelometer and a series-connected correlation spectrum analyzer. The nephelometer further includes a second scattered light detector disposed symmetrically about a first scattered light detector, a signal multiplier whose inputs are coupled to outputs of the first and second scattered light detectors, a low pass filter whose input is coupled to an output of the signal multiplier, and an output is coupled to a correlator of the spectrum analyzer, a conventional ampoule for a solvent being used as a measuring cuvette in the nephelometer.
    • 用于通过激光相关光谱(LSC)技术诊断涉及血浆分析的恶性疾病的方法包括以下步骤:制备天然血浆的弱稀释溶液,确定在1和1之间的频率范围内的光散射强度波动的光谱密度 1000Hz,区分频谱核心并从频谱核心包络的最大值和强度 - 宽度比的频率进行诊断,当诊断参数小于适当速率时,检测恶性疾病。 用于诊断恶性肿瘤的装置包括浊度计和串联相关频谱分析仪。 散光计进一步包括第二散射光检测器,该第二散射光检测器围绕第一散射光检测器对称地设置,信号乘法器,其输入耦合到第一和第二散射光检测器的输出;低通滤波器,其输入耦合到信号的输出 乘法器,并且输出耦合到频谱分析仪的相关器,用于溶剂的常规安瓿用作浊度计中的测量比色皿。
    • 38. 发明授权
    • Production of pyrrolopyrimidines
    • 吡咯并嘧啶的生产
    • US5349064A
    • 1994-09-20
    • US29310
    • 1993-03-08
    • Hiroshi AkimotoTakenori HitakaTetsuo Miwa
    • Hiroshi AkimotoTakenori HitakaTetsuo Miwa
    • A61K31/505A61P35/00C07D239/48C07D239/49C07D239/50C07D487/04
    • C07D239/48C07D239/50C07D487/04
    • There is provided an improved process for producing novel compounds represented by the general formula: ##STR1## wherein the ring A represents a pyrrole ring which may be hydrogenated; X represents an amino, hydroxyl or mercapto group; R.sup.1, R.sup.2 and R.sup.3 each being the same as or different from the other, represents hydrogen or an alkyl, alkenyl or alkynyl group which may be substituted; R.sup.4 represents OR.sup.5 wherein R.sup.5 represents hydrogen or a hydrocarbon group which may be substituted or NHCH(COOR.sup.6)CH.sub.2 CH.sub.2 COOR.sup.7 wherein R.sup.6 and R.sup.7 each represents hydrogen or a hydrocarbon group which may be substituted; and n represents an integer of 1 to 4, or a salt thereof from compounds represented by the general formula: ##STR2## wherein X, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and n are the same as defined above; Y.sup.1 and Y.sup.2 each represents oxygen or sulfur atom; R.sup.8 and R.sup.9 each, being the same as or different from the other, represents a hydrocarbon group which may be substituted, or salts thereof by an intramolecular ring closure reaction to form a pyrrolopyrimidine ring and, if necessary, reducing the pyrrole ring thus formed to a pyrroline ring. The compounds are useful as antitumor agents.
    • 提供了用于制备由以下通式表示的新化合物的改进方法:其中环+ E,crc / A /代表可被氢化的吡咯环; X表示氨基,羟基或巯基; R 1,R 2和R 3各自彼此相同或不同,表示氢或可被取代的烷基,烯基或炔基; R4表示OR5,其中R5表示氢或可被取代的烃基或NHCH(COOR6)CH2CH2COOR7,其中R6和R7各自表示氢或可被取代的烃基; 其中X,R1,R2,R3,R4和n与上述定义相同; n表示1〜4的整数,或其盐由通式: Y1和Y2各自表示氧或硫原子; R 8和R 9各自相同或不同,表示可以被取代的烃基,或其盐通过分子内闭环反应形成吡咯并嘧啶环,如果需要,将由此形成的吡咯环还原成 吡咯啉环。 该化合物可用作抗肿瘤剂。
    • 40. 发明授权
    • Maytansinoids, pharmaceutical compositions thereof and methods of use
thereof
    • 美登木素生物碱,其药物组合物及其使用方法
    • US4260608A
    • 1981-04-07
    • US92953
    • 1979-11-09
    • Osamu MiyashitaHiroshi Akimoto
    • Osamu MiyashitaHiroshi Akimoto
    • A61K31/535A61P35/00C07D498/18C07D498/16
    • C07D498/18
    • Novel maytansinoids of the formula: ##STR1## wherein R.sup.1 is hydrogen atom, an alkyl group which may optionally be substituted or a group of the formula: --A.sup.1 --Y.sup.1 wherein A.sup.1 is an alkylene group or a bond, and Y.sup.1 is a cycloalkyl, phenyl, indolyl or imidazolyl group which may optionally be substituted,R.sup.2 is hydrogen atom, an alkyl, cycloalkyl or benzyl group,R.sup.3 is hydrogen atom, an alkyl group which may optionally be substituted, alkoxy, bornyloxy, isobornyloxy, benzyloxy group or a group of the formula: --A.sup.2 --Y.sup.2 wherein A.sup.2 is an alkylene group or a bond, and Y.sup.2 is an alicyclic hydrocarbon, phenyl or heterocyclic group which may optionally be substituted,provided that R.sup.3 is not an unsubstituted C.sub.1-4 alkyl group when both R.sup.1 and R.sup.2 are methyl groups, have antimicrobial antimitotic and antitumor activities.
    • 新型美登木素素,其分子式如下:其中R 1为氢原子,可任意取代的烷基或下式基团-A1-Y1其中A1为亚烷基或键,Y1为环烷基, 苯基,吲哚基或咪唑基,其可以任选被取代,R 2是氢原子,烷基,环烷基或苄基,R 3是氢原子,可任意被取代的烷基,烷氧基,苄氧基, 其中A2是亚烷基或键,Y2是可任选被取代的脂环烃,苯基或杂环基,条件是当R 3不是未取代的C 1-4烷基时, 和R2是甲基,具有抗微生物抗生素和抗肿瘤活性。